Search

Displaying results 5401 - 5410 of 10000 in total
  1. Drug

    Laropiprant

    go.drugbank.com/drugs/DB11629
    ApprovedWithdrawn

    Laropiprant is an ingredient in the EMA-withdrawn product Pelzont.

  2. Drug

    Senicapoc

    go.drugbank.com/drugs/DB06280
    Investigational

    Senicapoc (ICA-17043) is a novel Gardos channel blocker.[A259068] It is being investigated for the treatment of sickle cell disease.

  3. Drug

    Tagetitoxin

    go.drugbank.com/drugs/DB04788
    Experimental

    Tagetitoxin is a bacterial phytotoxin. It preferentially inhibits eukaryotic RNA polymerase.

  4. Drug

    Ergosterol

    go.drugbank.com/drugs/DB04038
    ApprovedWithdrawn

    in ERGOCALCIFEROL. … A steroid of interest both because its biosynthesis in FUNGI is a target of ANTIFUNGAL AGENTS, notably AZOLES, and because when it is present in SKIN of animals, ULTRAVIOLET RAYS break a bond to result

  5. Drug

    CYNK-001

    go.drugbank.com/drugs/DB15722
    Investigational

    CYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.

  6. Drug

    Apoptone

    go.drugbank.com/drugs/DB06307
    Investigational

  7. Drug

    Meticrane

    go.drugbank.com/drugs/DB13284
    Approved

    Meticrane is a diuretic medication. It has been marketed in Japan under the trade name Arresten and is used to lower blood pressure [L5647].

  8. Drug

    AZD3409

    go.drugbank.com/drugs/DB04893
    Experimental

    AZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004.

  9. Drug

    Polyinosinic-polycytidylic acid

    go.drugbank.com/drugs/DB16467
    Investigational

    Synonyms: Poly I-C, Poly(I+C)Categories: Poly I, Poly I-C
  10. Drug

    Guanoxan

    go.drugbank.com/drugs/DB13211
    Approved

    Guanoxan is an antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage. … Guanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity.